Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NORWOOD, MASS., MAY 21, 2026 (GLOBE NEWSWIRE) -- CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: CRBP), A CLINICAL-STAGE COMPANY FOCUSED ON DEVELOPING PROMISING NEW THERAPIES IN ONCOLOGY AND OBESITY, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL HOST A CONFERENCE CALL AND WEBCAST ON TUESDAY, MAY 26 AT 8:00 A.M.

CORBUS PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF NISHANT SAXENA AS CHIEF BUSINESS OFFICER AND SCHEDULES A PRE-2026 ASCO CRB-701 DATA CONFERENCE CALL

VYJUVEK APPROVED FOR THE TREATMENT OF DEB FROM BIRTH WITH FLEXIBLE ADMINISTRATION OPTIONS SIMILAR TO THOSE ALREADY GRANTED IN THE UNITED STATES, EUROPEAN UNION, AND JAPAN VYJUVEK IS THE FIRST GENETIC MEDICINE APPROVED IN THE UNITED KINGDOM FOR THE TREATMENT OF DEB PITTSBURGH, MAY 18, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) TODAY ANNOUNCED THAT, ON MAY 15, 2026, THE UNITED KINGDOM MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) GRANTED MARKETING AUTHORIZATION TO VYJUVEK (BEREMAGENE GEPERPAVEC-SVDT) FOR THE TREATMENT OF WOUNDS IN PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB) WITH MUTATION(S) IN THE COLLAGEN TYPE VII ALPHA 1 CHAIN (COL7A1) GENE, FROM BIRTH. VYJUVEK IS THE FIRST GENETIC MEDICINE APPROVED IN THE UNITED KINGDOM FOR THE TREATMENT OF DEB AND IS DESIGNED TO ADDRESS THE ROOT CAUSE OF THE DISEASE BY DELIVERING FUNCTIONAL COPIES OF THE HUMAN COL7A1 GENE TO PROVIDE WOUND HEALING AND SUSTAINED FUNCTIONAL TYPE VII COLLAGEN PROTEIN EXPRESSION WITH REDOSING.

KRYSTAL BIOTECH ANNOUNCES UNITED KINGDOM MHRA APPROVAL OF VYJUVEK FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

PITTSBURGH, MAY 07, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE BOFA SECURITIES 2026 HEALTH CARE CONFERENCE ON MAY 13, 2026, IN LAS VEGAS. KRISH S. KRISHNAN, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL TAKE PART IN A FIRESIDE CHAT SCHEDULED AT 11:20 AM PT AND HOST INVESTOR MEETINGS THROUGHOUT THE DAY.

KRYSTAL BIOTECH TO PRESENT AT BOFA SECURITIES 2026 HEALTH CARE CONFERENCE

$116.4 MILLION IN 1Q VYJUVEK GLOBAL REVENUE AND $846.7 MILLION SINCE LAUNCH ENROLLMENT COMPLETE IN KB803 (CORNEAL ABRASIONS IN DEB PATIENTS) REGISTRATIONAL STUDY ON TRACK FOR KB803 AND KB801 (NK) REGISTRATIONAL DATA READOUTS IN 2026 FDA GRANTS PLATFORM TECHNOLOGY DESIGNATION FOR KB407 (CF) AND KB111 (HHD) STRONG BALANCE SHEET, ENDING THE QUARTER WITH $1.0 BILLION IN CASH AND INVESTMENTS PITTSBURGH, MAY 04, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDING MARCH 31, 2026 AND PROVIDED A BUSINESS UPDATE. FOLLOWING A SUCCESSFUL 2025, WE ARE ENTERING 2026 WITH STRONG MOMENTUM, INCLUDING TWO POTENTIAL REGISTRATIONAL STUDY READOUTS AND CONTINUED GLOBAL EXPANSION FOR VYJUVEK, SAID KRISH S.

KRYSTAL BIOTECH ANNOUNCES FIRST QUARTER 2026 FINANCIAL AND OPERATING RESULTS

PITTSBURGH, APRIL 30, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT THE COMPANY WILL BE PRESENTING ON MULTIPLE PROGRAMS AT UPCOMING SCIENTIFIC CONFERENCES BEING HELD IN MAY AND JUNE.

KRYSTAL BIOTECH TO PRESENT AT UPCOMING SCIENTIFIC CONFERENCES

PITTSBURGH, APRIL 21, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT IT WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON MONDAY, MAY 4, 2026, PRIOR TO THE OPEN OF U.S. MARKETS.

KRYSTAL BIOTECH TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 4, 2026

$107.1 MILLION IN 4Q VYJUVEK REVENUE AND $730.3 MILLION SINCE U.S. LAUNCH FDA GRANTED RMAT TO KB707 FOR THE TREATMENT OF ADVANCED NSCLC AND FAST TRACK DESIGNATION TO KB111 FOR THE TREATMENT OF HHD STRONG BALANCE SHEET, ENDING THE QUARTER WITH $955.9 MILLION IN CASH AND INVESTMENTS PITTSBURGH, FEB. 17, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDING DECEMBER 31, 2025 AND PROVIDED A BUSINESS UPDATE. IN 2025, KRYSTAL MADE MEANINGFUL PROGRESS ON OUR MISSION TO SERVE PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA AROUND THE WORLD, WHILE CONTINUING TO BUILD THE GLOBAL INFRASTRUCTURE REQUIRED TO SCALE OUR IMPACT, SAID KRISH S.

KRYSTAL BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL AND OPERATING RESULTS

PITTSBURGH, FEB. 10, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT IT WILL REPORT ITS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON TUESDAY, FEBRUARY 17, 2026, PRIOR TO THE OPEN OF U.S. MARKETS.

KRYSTAL BIOTECH TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON FEBRUARY 17, 2026

PRELIMINARY 4Q 2025 VYJUVEK NET REVENUE OF $106 MILLION TO $107 MILLION ROBUST CLINICAL PIPELINE WITH MULTIBILLION DOLLAR OPPORTUNITIES AND STRONG BALANCE SHEET FOR SUSTAINED GROWTH PITTSBURGH, JAN. 11, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC . (THE COMPANY) (NASDAQ: KRYS) TODAY ANNOUNCED SELECTED PRELIMINARY UNAUDITED 2025 FINANCIAL RESULTS, INCLUDING FOURTH QUARTER AND FULL YEAR 2025 VYJUVEK NET PRODUCT REVENUE, AND OUTLINED THE COMPANY'S STRATEGIC VISION TO DRIVE THE NEXT STAGE OF GROWTH OF ITS RARE DISEASE BUSINESS.

KRYSTAL BIOTECH PROVIDES BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

PITTSBURGH, NOV. 26, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC . (THE COMPANY) (NASDAQ: KRYS) TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE ON DECEMBER 3, 2025, IN MIAMI. KRISH S. KRISHNAN, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL TAKE PART IN A FIRESIDE CHAT SCHEDULED AT 10:00 AM ET AND HOST INVESTOR MEETINGS THROUGHOUT THE DAY.

Krystal Biotech, Inc.

KRYS

Price

Financial Reports

No items found.

Press Releases

Krystal Biotech, Inc.

KRYS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

KRYS